Feed Top Reports Pricing

⌘K

00:15:03·555d

SECFiling

SEC Form EFFECT filed by Kintara Therapeutics Inc.

KTRA· Kintara Therapeutics Inc.

Health Care

Original source

Companies

KTRA
Kintara Therapeutics Inc.
Health Care

Recent analyst ratings

Jan 20UpdateHC Wainwright & Co.$3.00
Sep 30UpdateAegis Capital$5.00
Sep 28UpdateHC Wainwright & Co.$6.00

Related

PR32d
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
PR288d
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
INSIDER548d
SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis
INSIDER548d
New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)
INSIDER548d
SEC Form 4 filed by Director Ng George K
INSIDER548d
New insider Ng George K claimed no ownership of stock in the company (SEC Form 3)
INSIDER548d
SEC Form 4 filed by Director List Alan
INSIDER548d
New insider List Alan claimed no ownership of stock in the company (SEC Form 3)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022